ArticleJournal of mathematical biology2025
Multi-objective control to schedule therapies for acute viral infections.
Article in Journal of mathematical biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Antiviral therapies can yield different outcomes depending on their scheduling: a highly effective drug may produce treatment results ranging from successful to inconsequential, depending on therapeutic timing, dosing intervals, and dosage. The effectiveness of antiviral therapies can be assessed using mathematical models that describe viral spread within a host. In this work, we conduct a study based on the dynamic characterization of a target-cell model to address a multi-objective control problem aimed at designing highly effective and host-customizable antiviral therapies. These therapies involve finite-time antiviral treatments that minimize the viral load peak and the infection final size until infection clearance, while simultaneously reducing the total amount of drug intake as much as possible. Two optimization-based control strategies are proposed: a fixed-dose and a variable-dose approach. The variable-dose strategy achieves superior performance by explicitly considering the system dynamics in the design of the control. Simulation results, based on an identified model for COVID-19 patients treated with Paxlovid, illustrate the potential benefits of the proposed strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.